80
Participants
Start Date
September 17, 2025
Primary Completion Date
March 22, 2028
Study Completion Date
March 22, 2029
JS207 in combination with 9MW2821
JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), 9MW2821 will be administered intravenously at a dose of 1.25 m.g/kg (D1 and D8, Q3W)
JS207 in combination with Albumin paclitaxel
JS207 will be administered intravenously at a dose of 10 mg/kg (D1, Q3W), Albumin paclitaxel will be administered intravenously at a dose of 125 mg/m2 (D1 and D8, Q3W).
NOT_YET_RECRUITING
Peking University People's Hospital, Beijing
RECRUITING
The Fifth Medical Center of PLA General Hospital, Beijing
RECRUITING
The First Hospital of China Medical University, Shenyang
RECRUITING
Liaoning Cancer Hospital&Institute, Shenyang
RECRUITING
The Second Hospital of Dalian Medical University, Dalian
RECRUITING
Jilin University First Hospital, Changchun
RECRUITING
Jiangsu Cancer Hospital, Nanjing
NOT_YET_RECRUITING
Jiangsu Province Hospital, Nanjing
RECRUITING
The Affiliated Hospital of Qingdao University, Qingdao
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Henan Cancer Hospital, Zhangzhou
RECRUITING
The First Affiliated Hospital of Xi'an Jiaotong University, Xian
RECRUITING
Xi'an International Medical Center Hospital, Xian
NOT_YET_RECRUITING
Ceneral Hosipital of Ningxia Medical University, Yinchuan
RECRUITING
Affiliated Tumor Hospital of Xinjiang Medical University, Ürümqi
RECRUITING
Affiliated Hospital of Hebei University, Baoding
Shanghai Junshi Bioscience Co., Ltd.
OTHER